Analysts have been eager to weigh in on the Healthcare sector with new ratings on C4 Therapeutics (CCCC – Research Report), ACADIA Pharmaceuticals (ACAD – Research Report) and Disc Medicine (IRON – Research Report).
C4 Therapeutics (CCCC)
In a report issued on May 10, Bradley Canino from Stifel Nicolaus maintained a Buy rating on C4 Therapeutics, with a price target of $14.00. The company’s shares closed last Friday at $6.16.
According to TipRanks.com, Canino is a 4-star analyst with an average return of
Currently, the analyst consensus on C4 Therapeutics is a Moderate Buy with an average price target of $12.57.
See Insiders’ Hot Stocks on TipRanks >>
ACADIA Pharmaceuticals (ACAD)
Stifel Nicolaus analyst Paul Matteis maintained a Hold rating on ACADIA Pharmaceuticals on May 10 and set a price target of $21.00. The company’s shares closed last Friday at $15.25, close to its 52-week low of $15.11.
According to TipRanks.com, Matteis is a 4-star analyst with an average return of
ACADIA Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $28.28, an 84.8% upside from current levels. In a report issued on May 6, Oppenheimer also maintained a Hold rating on the stock with a $19.00 price target.
Disc Medicine (IRON)
Stifel Nicolaus analyst Benjamin Burnett maintained a Buy rating on Disc Medicine on May 10 and set a price target of $72.00. The company’s shares closed last Friday at $30.36, close to its 52-week low of $25.60.
According to TipRanks.com, Burnett has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Disc Medicine is a Strong Buy with an average price target of $53.88, implying a 74.7% upside from current levels. In a report issued on May 9, BMO Capital also maintained a Buy rating on the stock with a $50.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CCCC:
- C4 Therapeutics price target raised to $8 from $7 at Wells Fargo
- C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
- C4 Therapeutics reports Q1 EPS (41c), consensus (35c)
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum
